Platelet Transfusion Refractoriness
- Conditions
- Platelet Transfusion Refractoriness
- Interventions
- Procedure: platelet transfusion
- Registration Number
- NCT05399693
- Lead Sponsor
- Institut de cancérologie Strasbourg Europe
- Brief Summary
Platelet Transfusion Refractoriness is one of the severe complications after multiple transfusions in patients with severe thrombopenia. Platelet Transfusion Refractoriness is characterized by inefficient transfusion and arise from allo-antibodies specific of platelets antigenes, mostly carried by HLA-I molecules.
- Detailed Description
A preliminary study has shown different isotypes of anti-HLA I in patients with Platelet Transfusion Refractoriness. Our hypothesis is that the type of anti-HLA I antibodies (recognised epitope, quantity, isotype) should establish predictive and diagnostic criteria for Platelet Transfusion Refractoriness.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 50
- Adult patient with Hematopoietic stem cells graft (autograft or allograft) or with acute leukemia with the indication of platelet transfusion.
- Patient under guardianship
- Minor patient
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients without Platelet Transfusion Refractoriness platelet transfusion - Patients with Platelet Transfusion Refractoriness platelet transfusion -
- Primary Outcome Measures
Name Time Method Research of predictive criteria of Platelet transfusion refractoriness blood samples before the transfusion of each chemotherapy cycle Characterisation of anti-HLA I antibodies (recognised epitopes and isotypes) associated to Platelet transfusion refractoriness
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Institut de cancérologie Strasbourg Europe
🇫🇷Strasbourg, France